Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease: reply
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Sir, We appreciated reading the letter of Piga et al. [1] in response to our recent report concerning the detection of autoantibodies directed to anti-dsDNA in SLE [2]. In this letter, they discuss their own results of serial measurements of anti-dsDNA using RIA by the Farr assay [3]. Comparable findings were obtained regarding the number of patients who had an increased anti-dsDNA >20% level in the 6 months prior to flare occurrence. Moreover, they demonstrated that intensification in immunosuppressive treatment could be effective in preventing flares in patients who experienced an increase in anti-dsDNA level ⩾50% without any symptoms (n = 64), as none of the patients who were treated (n = 15) had a flare, but 32.6% (16/49) of the non-treated patients did experienced a flare. So both our studies confirm the fact that monitoring anti-dsDNA levels is important in the follow-up of SLE patients. Their main concern is that by using enzyme-labelled anti-isotype assay (EliA), which has a high specificity but a lower sensitivity in quiescent SLE, early changes in anti-dsDNA levels are missed. However, when comparing EliA and the Farr assay, as we did in our study, the same percentages of patients with an increase of anti-dsDNA before an exacerbation were found. Also when we apply this at ⩾50% threshold instead of a ⩾20% increase, only two patients would have been missed using EliA, but also by using Farr. So, even though EliA is less sensitive in quiescent disease, an increase in anti-dsDNA levels probably will be detected by using this technique. As Piga et al. stated, a relative increase is much more important than absolute values, as steadily increased anti-dsDNA do not predict a flare. Of course, prospective studies using EliA should be performed to confirm these findings. Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript. Disclosure statement: The authors have declared no conflicts of interest.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A substantial portion (23%) of the controls that had positive antibodies by Farr received anti-TNF treatment [41].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [41]
In the citing paper
“A positive correlation was reported for FEIA [41], [68] and for CIA [48], [67].”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [41]
In the citing paper
“FEIA showed higher specificity, but lower sensitivity to detect anti-dsDNA antibodies in quiescent SLE patients compared to Farr.”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [41]
In the citing paper
“Additionally, FEIA showed higher specificity to predict flares in lupus nephritis patients, while Farr was better to predict exacerbations in non-nephritis patients.”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [41]
In the citing paper
“De Leeuw et al. included control patients on anti-TNF treatment and found a low specificity for Farr assay.”
From Laboratory evaluation of anti-dsDNA antibodies. (2022) · cites this paper as [41]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Floris, A., Piga, M., Cauli, A., & Mathieu, A. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.02.019 · Cited by 74
de Leeuw, K., Bungener, L., Roozendaal, C., Bootsma, H., & Stegeman, C. A. (2017) · Rheumatology · doi:10.1093/rheumatology/kew462 · Cited by 24
Self-citationPiga, M., Floris, A., Mathieu, A., & Cauli, A. (2017) · Rheumatology · doi:10.1093/rheumatology/kex313 · Cited by 2
Cited by
Anti-dsDNA Testing Specificity for Systemic Lupus Erythematosus: A Systematic Review.
Orme, M. E., Voreck, A., Aksouh, R., & Schreurs, M. W. J. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab146 · Cited by 30
Laboratory evaluation of anti-dsDNA antibodies.
Cockx, M., Van Hoovels, L., De Langhe, E., Lenaerts, J., Thevissen, K., Persy, B., Bonroy, C., Vercammen, M., & Bossuyt, X. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.12.029 · Cited by 30
Becker, Y. L. C., Gagné, J., Julien, A., Lévesque, T., Allaeys, I., Gougeard, N., Rubio, V., Boisvert, F., Jean, D., Wagner, E., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42082 · Cited by 26
He, S., Wu, X., Li, L., Jiang, K., He, Q., & Xie, L. (2023) · Lupus · doi:10.1177/09612033231179888 · Cited by 2
Metadata
- Authors
- de Leeuw, K., Bungener, L., Roozendaal, C., Bootsma, H., & Stegeman, C. A.
- Affiliations
- University Medical Center Groningen (NL)
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-11
- Volume
- 56
- Issue
- 11
- Pages
- 2039-2040
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2744229363
- Semantic Scholar
- 7e046c02a272bb67f40bf1fa831b4054e9a98e83
- Cited by
- 19
- References
- 3
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 3 · 2018: 3
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Lara D. Veeken (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- anti-dsDNA antibodies, systemic lupus erythematosus, disease flare prediction, Farr assay, assay sensitivity and specificity, biomarkers, quiescent disease
- MeSH terms
- Antibodies, Antinuclear, Autoantibodies, DNA, Humans, Lupus Erythematosus, Systemic, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease: reply. https://app.cochat.ai/papers/10.1093/rheumatology/kex314
- The paper
- de Leeuw, K., Bungener, L., Roozendaal, C., Bootsma, H., & Stegeman, C. A. (2017). Comment on: Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease: reply. Rheumatology. https://doi.org/10.1093/rheumatology/kex314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.